注射用铁剂治疗缺铁性贫血的疗效：一项随机对照试验的荟萃分析。

The Efficacy of Ferumoxytol for Iron Deficiency Anemia: A Meta-Analysis of Randomized Controlled Trials.

机构信息

Department of Hematology-Oncology, Taizhou Hospital of Zhejiang Province, Linhai City, China.

Department of Emergency, Taizhou Hospital of Zhejiang Province, Linhai City, China.

出版信息

Acta Haematol. 2019;142(3):125-131. doi: 10.1159/000498937. Epub 2019 Aug 21.

DOI:10.1159/000498937

PMID:31434073

Abstract

INTRODUCTION

This systematic review and meta-analysis aims to explore the influence of ferumoxytol versus placebo on iron deficiency anemia.

METHODS

We search for randomized controlled trials (RCTs) assessing the effect of ferumoxytol on iron deficiency anemia on PubMed, EMbase, Web of science, EBSCO, and Cochrane library databases. This meta-analysis is performed using the random-effects model.

RESULTS

Four RCTs are included in the meta-analysis. Compared with the control group for iron deficiency anemia, intravenous ferumoxytol can significantly improve the proportion of patients with a ≥20 g/L hemoglobin (Hb) increase (RR = 18.43; 95% CI = 7.29-46.57; p < 0.00001), the proportion of patients with an Hb level ≥120 g/L (RR = 18.55; 95% CI = 8.66-39.72; p < 0.00001), transferrin saturation (mean difference = 11.08; 95% CI = 9.86-12.31; p < 0.00001) and FACIT-fatigue score (mean difference = 4.60; 95% CI = 3.21-6.00; p < 0.00001), but has no remarkable influence on adverse events (RR = 1.33; 95% CI = 0.84-2.10; p = 0.22), serious adverse events (RR = 1.22; 95% CI = 0.74-2.02; p = 0.44), and death (RR = 0.32; 95% CI = 0.05-1.95; p = 0.22).

CONCLUSIONS

Intravenous ferumoxytol can provide the important benefits for iron deficiency anemia.

摘要

简介

本系统评价和荟萃分析旨在探讨 ferumoxytol 与安慰剂对缺铁性贫血的影响。

方法

我们在 PubMed、EMbase、Web of science、EBSCO 和 Cochrane 图书馆数据库中搜索评估 ferumoxytol 对缺铁性贫血影响的随机对照试验（RCT）。本荟萃分析采用随机效应模型进行。

结果

荟萃分析纳入了 4 项 RCT。与缺铁性贫血对照组相比，静脉注射 ferumoxytol 可显著提高血红蛋白（Hb）升高≥20 g/L 的患者比例（RR=18.43；95%CI=7.29-46.57；p<0.00001），Hb 水平≥120 g/L 的患者比例（RR=18.55；95%CI=8.66-39.72；p<0.00001）、转铁蛋白饱和度（均数差=11.08；95%CI=9.86-12.31；p<0.00001）和 FACIT-疲劳评分（均数差=4.60；95%CI=3.21-6.00；p<0.00001），但对不良事件（RR=1.33；95%CI=0.84-2.10；p=0.22）、严重不良事件（RR=1.22；95%CI=0.74-2.02；p=0.44）和死亡（RR=0.32；95%CI=0.05-1.95；p=0.22）无显著影响。